Szaumkessel Marcin, Wojciechowska Sonia, Janiszewska Joanna, Zemke Natalia, Byzia Ewa, Kiwerska Katarzyna, Kostrzewska-Poczekaj Magdalena, Ustaszewski Adam, Jarmuz-Szymczak Malgorzata, Grenman Reidar, Wierzbicka Malgorzata, Bartochowska Anna, Szyfter Krzysztof, Giefing Maciej
1 Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.
2 Department of Otorhinolaryngology-Head and Neck Surgery, Turku University Hospital and University of Turku, Turku, Finland.
Tumour Biol. 2017 Mar;39(3):1010428317691427. doi: 10.1177/1010428317691427.
Cellular processes like differentiation, mitotic cycle, and cell growth are regulated by tyrosine kinases with known oncogenic potential and tyrosine phosphatases that downmodulate the first. Therefore, tyrosine phosphatases are recurrent targets of gene alterations in human carcinomas. We and others suggested recently a tumor suppressor function of the PTPRD tyrosine phosphatase and reported homozygous deletions of the PTPRD locus in laryngeal squamous cell carcinoma. In this study, we investigated other gene-inactivating mechanisms potentially targeting PTPRD, including loss-of-function mutations and also epigenetic alterations like promoter DNA hypermethylation. We sequenced the PTPRD gene in eight laryngeal squamous cell carcinoma cell lines but did not identify any inactivating mutations. In contrast, by bisulfite pyrosequencing of the gene promoter region, we identified significantly higher levels of methylation (p = 0.001 and p = 0.0002, respectively) in 9/14 (64%) laryngeal squamous cell carcinoma cell lines and 37/79 (47%) of primary laryngeal squamous cell carcinoma tumors as compared to normal epithelium of the upper aerodigestive tract. There was also a strong correlation (p = 0.0001) between methylation and transcriptional silencing for the PTPRD gene observed in a cohort of 497 head and neck tumors from The Cancer Genome Atlas dataset suggesting that DNA methylation is the main mechanism of PTPRD silencing in these tumors. In summary, our data provide further evidence of the high incidence of PTPRD inactivation in laryngeal squamous cell carcinoma. We suggest that deletions and loss-of-function mutations are responsible for PTPRD loss only in a fraction of cases, whereas DNA methylation is the dominating mechanism of PTPRD inactivation.
细胞分化、有丝分裂周期和细胞生长等细胞过程由具有已知致癌潜力的酪氨酸激酶以及下调前者的酪氨酸磷酸酶调控。因此,酪氨酸磷酸酶是人类癌症中基因改变的常见靶点。我们和其他研究团队最近提出了PTPRD酪氨酸磷酸酶的肿瘤抑制功能,并报道了喉鳞状细胞癌中PTPRD基因座的纯合缺失。在本研究中,我们调查了其他可能靶向PTPRD的基因失活机制,包括功能丧失突变以及启动子DNA高甲基化等表观遗传改变。我们对8个喉鳞状细胞癌细胞系中的PTPRD基因进行了测序,但未发现任何失活突变。相反,通过对基因启动子区域进行亚硫酸氢盐焦磷酸测序,我们发现与上呼吸道消化道正常上皮相比,9/14(64%)的喉鳞状细胞癌细胞系和37/79(47%)的原发性喉鳞状细胞癌肿瘤中甲基化水平显著更高(分别为p = 0.001和p = 0.0002)。在来自癌症基因组图谱数据集的497例头颈部肿瘤队列中观察到,PTPRD基因的甲基化与转录沉默之间也存在很强的相关性(p = 0.0001),这表明DNA甲基化是这些肿瘤中PTPRD沉默的主要机制。总之,我们的数据进一步证明了喉鳞状细胞癌中PTPRD失活的高发生率。我们认为,缺失和功能丧失突变仅在一部分病例中导致PTPRD缺失,而DNA甲基化是PTPRD失活的主要机制。